What is it? Why is it important?

Pre-Screening takes place before participants give consent to study participation (e.g. sign the Informed Consent Form (ICF)).  The aim of pre-screening is to be able to identify potential study participants eligible for the study.

 

At a participating study site(s), study eligibility is evaluated by pre-screening potential participants and their ability to fulfil the main inclusion/exclusion criteria of the study y (e.g. medical history, diagnosis, co-morbidities, disease stage, age, gender, healthy volunteers, pregnancy, treatment naïve)

 

No study specific procedures are performed during PS. Study specific procedures are only implemented once participants have signed the ICF.

 

The access and availability of potential study participants at a given clinic, will highly affect the ability to recruit participants for the planned study.

What do I need to do?

As a Site-INV and based on study eligibility:

  • Inform physicians at your clinic about the study and ask them to review patient files from potential patients under their care. Instruct them that potential study candidates should only be approached during scheduled consultations, or by phone

 

As a Site-INV, you can only contact potential patients who did confirm to their treating physician that they:

  • Had an interest in study participation
  • Did agree to be contacted by study representatives (e.g. SP-INV/Site-INV, study nurse)

 

Once an eligible patient is interested in study participation, follow and comply with the informed consent procedures defined for your study, and:

  • Provide the patient with applicable study information and consent documents (e.g. PIS, ICF)
  • Schedule a “screening and consent” visit

 

In the Pre-Screening-log list all patients that were pre-screened for the study. Include both eligible and non-eligible patients, irrespective whether they agreed to study participation or not. File the Pre-Screening-log in the ISF

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guidelines

  • C.3.1 Essentiality of Trial Records
Abbreviations
  • CTU – Clinical Trials Unit
  • ICF – Informed Consent Form
  • ICH-GCP – International Council for Harmonisation - Good Clinical Practice
  • ISF – Investigator Site File
  • PIS – Participant Information Sheet
  • PS – Pre-Screening
  • Site-INV – Site-Investigator
  • SP-INV – Sponsor Investigator
Conduct ↦ Management ↦ Participant Recruitment ↦ Pre-Screening
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Management ↦ Participant Recruitment ↦ Pre-Screening